Delivery Order SPE2DR25D1104-SPE2DR26FK384
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Prograf 1 mg capsules (100-count) with a ceiling value of $9,453.72. This firm fixed-price contract, with an ultimate completion date of November 5, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award was...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Prograf 1 mg capsules (100-count units) on November 5, 2025, with a ceiling value of $5,083.18. This non-competitive, firm fixed-price delivery order is expected to be completed by November 6, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under the company's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of Prograf 1 mg capsules in quantities of 100 units. This contract, which is a child order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX, valued at $999.9 million through December 2026), carries a ceiling value of $2,747.52 and employs firm fixed-price pricing with no set-aside designation. The product will be...
- The Defense Logistics Agency awarded a $18,879.92 delivery order to AmerisourceBergen Drug Corp for Prograf 1 mg capsules (100-count units) on July 28, 2025, with completion scheduled for July 29, 2025. This firm fixed-price contract, which carries no set-aside designation, will be performed at the contractor's facility in Conshohocken, Pennsylvania. Prograf (tacrolimus) is an immunosuppressant medication commonly used in transplant medicine and autoimmune disease management, representing part...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,423.23 to supply Prograf 1 mg capsules (100-count units) with a firm fixed price structure. This non-set-aside competitive award was executed on November 18, 2025, with an ultimate completion date of November 19, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Prograf (tacrolimus) is an immunosuppressant medication commonly used in transplant...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,120.30 to supply 100 capsules of Prograf 0.5 mg, a pharmaceutical product used in immunosuppressive therapy. The contract, issued on November 3, 2025, with an ultimate completion date of November 4, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award through the federal procurement process. Performance will be fulfilled from AmerisourceBergen's Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $14,638.85 to AmerisourceBergen Drug Corp for the supply of Prograf 5 mg capsules (100 count) on November 3, 2025, with completion scheduled for November 4, 2025. This is a firm fixed price delivery order with no set-aside designation, performed at the contractor's corporate office in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal medical supply needs, likely for...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,663.57 on October 20, 2025, for the supply of Prograf 0.5 mg capsules (100-count units). This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of October 21, 2025. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $3,999.03 to AmerisourceBergen Drug Corp for 100 capsules of Prograf 0.5 mg on October 29, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating the award was made through open competition. The pharmaceutical product will be delivered to the contractor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of October 30, 2025. This delivery order is a child...
- The Defense Logistics Agency awarded a $1,738.12 delivery order to AmerisourceBergen Drug Corp on June 25, 2025, for the supply of Prograf 1 mg capsules (100-count units). This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The pharmaceutical product will be delivered to AmerisourceBergen's corporate...
- SPE2DR25D1104Indefinite Delivery Contract
- SPE2DR25D1104-SPE2DR26FK384Delivery Order
The Defense Logistics Agency awarded a $5,179.38 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Prograf 1 mg on November 18, 2025, with completion scheduled for November 19, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed price pricing and represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military and veteran healthcare systems. Prograf (tacrolimus) is an immunosuppressant medication commonly used in post-transplant care and other clinical applications requiring immune system suppression, reflecting the specialized pharmaceutical needs served through the DLA's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.2k | 11/18/25 |